DESIGN THERAPEUTICS INC (DSGN) Stock News
NASDAQ:DSGN - Nasdaq - US25056L1035 - Common Stock - Currency: USD
DSGN Latest News, Press Relases and Analysis
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application...
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments...
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs...
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
Lam Research Corporation (LRCX): Jim Cramer Is Blunt — “Lam Is a Gem”
We recently published Jim Cramer’s Surprised About US Travel As He Discusses These 18 Stocks. In this article, we are going to take a look at where Lam Research Corporation (NASDAQ:LRCX) stands against other stocks that Jim Cramer discussed. In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented on the growing […]
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing...
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025 Dosing...
Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing...
Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing...
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to...
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with...
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them.